دورية أكاديمية
أعرض في EDS

Inhibition of Monoamine Oxidases by Pyridazinobenzylpiperidine Derivatives.

التفاصيل البيبلوغرافية
العنوان: Inhibition of Monoamine Oxidases by Pyridazinobenzylpiperidine Derivatives.
المؤلفون: Oh JM; Department of Pharmacy, and Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Republic of Korea., Zenni YN; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Inonu University, Malatya 44210, Türkiye., Özdemir Z; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Inonu University, Malatya 44210, Türkiye., Kumar S; Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi 682041, India., Kılıç S; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Inonu University, Malatya 44210, Türkiye., Akdağ M; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Türkiye., Özçelik AB; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Ankara 06100, Türkiye., Kim H; Department of Pharmacy, and Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Republic of Korea., Mathew B; Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi 682041, India.
المصدر: Molecules (Basel, Switzerland) [Molecules] 2024 Jun 28; Vol. 29 (13). Date of Electronic Publication: 2024 Jun 28.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, c1995-
مواضيع طبية MeSH: Monoamine Oxidase Inhibitors*/pharmacology , Monoamine Oxidase Inhibitors*/chemistry , Monoamine Oxidase Inhibitors*/chemical synthesis , Monoamine Oxidase*/metabolism , Piperidines*/pharmacology , Piperidines*/chemistry, Humans ; Structure-Activity Relationship ; Pyridazines/chemistry ; Pyridazines/pharmacology ; Pyridazines/chemical synthesis ; Molecular Docking Simulation ; Molecular Structure
مستخلص: Monoamine oxidase inhibitors (MAOIs) have been crucial in the search for anti-neurodegenerative medications and continued to be a vital source of molecular and mechanistic diversity. Therefore, the search for selective MAOIs is one of the main areas of current drug development. To increase the effectiveness and safety of treating Parkinson's disease, new scaffolds for reversible MAO-B inhibitors are being developed. A total of 24 pyridazinobenzylpiperidine derivatives were synthesized and evaluated for MAO. Most of the compounds showed a higher inhibition of MAO-B than of MAO-A. Compound S5 most potently inhibited MAO-B with an IC 50 value of 0.203 μM, followed by S16 (IC 50 = 0.979 μM). In contrast, all compounds showed weak MAO-A inhibition. Among them, S15 most potently inhibited MAO-A with an IC 50 value of 3.691 μM, followed by S5 (IC 50 = 3.857 μM). Compound S5 had the highest selectivity index (SI) value of 19.04 for MAO-B compared with MAO-A. Compound S5 (3-Cl) showed greater MAO-B inhibition than the other derivatives with substituents of -Cl > -OCH 3 > -F > -CN > -CH 3 > -Br at the 3-position. However, the 2- and 4-position showed low MAO-B inhibition, except S16 (2-CN). In addition, compounds containing two or more substituents exhibited low MAO-B inhibition. In the kinetic study, the K i values of S5 and S16 for MAO-B were 0.155 ± 0.050 and 0.721 ± 0.074 μM, respectively, with competitive reversible-type inhibition. Additionally, in the PAMPA, both lead compounds demonstrated blood-brain barrier penetration. Furthermore, stability was demonstrated by the 2V5Z- S5 complex by pi-pi stacking with Tyr398 and Tyr326. These results suggest that S5 and S16 are potent, reversible, selective MAO-B inhibitors that can be used as potential agents for the treatment of neurological disorders.
References: Mol Divers. 2023 Mar 28;:. (PMID: 36977955)
Pharmacol Rep. 2020 Jun;72(3):692-704. (PMID: 32144745)
Eur J Med Chem. 2024 Aug 5;274:116566. (PMID: 38838545)
Bioorg Chem. 2024 Apr;145:107213. (PMID: 38368658)
Curr Comput Aided Drug Des. 2024;20(5):474-485. (PMID: 37138424)
Bioorg Chem. 2020 Sep;102:104035. (PMID: 32721780)
Eur J Med Chem. 2016 Nov 29;124:713-728. (PMID: 27639363)
Eur J Med Chem. 2003 Mar;38(3):223-32. (PMID: 12667689)
Eur J Med Chem. 2024 Apr 5;269:116266. (PMID: 38490063)
Bioorg Chem. 2019 Mar;83:317-325. (PMID: 30396116)
Nat Commun. 2023 Apr 20;14(1):2174. (PMID: 37080960)
Eur J Med Chem. 2015 Jan 7;89:32-41. (PMID: 25462223)
ACS Omega. 2023 Feb 07;8(7):6908-6917. (PMID: 36844523)
J Med Chem. 1983 Aug;26(8):1144-9. (PMID: 6876082)
Molecules. 2021 Jul 06;26(14):. (PMID: 34299393)
Eur J Med Chem. 2017 Oct 20;139:1-11. (PMID: 28797881)
CNS Neurol Disord Drug Targets. 2023;22(3):329-352. (PMID: 34970960)
J Neural Transm (Vienna). 2023 Jun;130(6):847-861. (PMID: 36964457)
Med Chem. 2024;20(3):245-267. (PMID: 37711126)
Lancet Neurol. 2022 Apr;21(4):381-392. (PMID: 35131038)
CNS Drugs. 2017 Feb;31(2):169-176. (PMID: 28110399)
Eur J Med Chem. 2021 Jan 1;209:112946. (PMID: 33129590)
J Med Chem. 2007 Nov 15;50(23):5848-52. (PMID: 17915852)
J Comput Chem. 2010 Jan 30;31(2):455-61. (PMID: 19499576)
Molecules. 2020 Nov 17;25(22):. (PMID: 33212876)
Bioorg Chem. 2018 Apr;77:74-83. (PMID: 29334622)
Heliyon. 2023 Dec 12;10(1):e23407. (PMID: 38187336)
RSC Med Chem. 2024 Feb 8;15(3):1038-1045. (PMID: 38516591)
Bioorg Chem. 2021 Oct;115:105203. (PMID: 34371375)
Molecules. 2022 Dec 02;27(23):. (PMID: 36500572)
Bioorg Med Chem Lett. 2011 Oct 1;21(19):5774-7. (PMID: 21875806)
Molecules. 2023 Jul 18;28(14):. (PMID: 37513351)
Molecules. 2022 Jun 13;27(12):. (PMID: 35744926)
J Chem Inf Model. 2011 Oct 24;51(10):2778-86. (PMID: 21919503)
Future Med Chem. 2020 Jan;12(1):37-50. (PMID: 31710239)
معلومات مُعتمدة: TYL-2023-3186 Research Foundation of ˙Inönü University
فهرسة مساهمة: Keywords: benzylpiperidine; molecular docking; monoamine oxidase inhibitors; pyridazinone
المشرفين على المادة: 0 (Monoamine Oxidase Inhibitors)
EC 1.4.3.4 (Monoamine Oxidase)
0 (Piperidines)
0 (Pyridazines)
تواريخ الأحداث: Date Created: 20240713 Date Completed: 20240713 Latest Revision: 20240715
رمز التحديث: 20240715
مُعرف محوري في PubMed: PMC11243598
DOI: 10.3390/molecules29133097
PMID: 38999047
قاعدة البيانات: MEDLINE
الوصف
تدمد:1420-3049
DOI:10.3390/molecules29133097